Complement-Opsonized Nano-Carriers Are Bound by Dendritic Cells (DC) via Complement Receptor (CR)3, and by B Cell Subpopulations via CR-1/2, and Affect the Activation of DC and B-1 Cells

The development of nanocarriers (NC) for biomedical applications has gained large interest due to their potential to co-deliver drugs in a cell-type-targeting manner. However, depending on their surface characteristics, NC accumulate serum factors, termed protein corona, which may affect their cellu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bednarczyk, Monika, Medina-Montano, Carolina, Fittler, Frederic Julien, Stege, Henner, Roskamp, Meike, Kuske, Michael, Langer, Christian, Vahldieck, Marco, Montermann, Evelyn, Tubbe, Ingrid, Röhrig, Nadine, Dzionek, Andrzej, Grabbe, Stephan, Bros, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001596/
https://www.ncbi.nlm.nih.gov/pubmed/33799879
http://dx.doi.org/10.3390/ijms22062869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001596/
https://www.ncbi.nlm.nih.gov/pubmed/33799879
http://dx.doi.org/10.3390/ijms22062869

Ejemplares similares